OBJECTIVES: To measure device-associated infection (DAI) rates, microbiological profiles, bacterial resistance, and attributable mortality in intensive care units (ICUs) in hospitals in Peru that are members of the International Nosocomial Infection Control Consortium (INICC). METHODS: Prospective cohort surveillance of DAIs was conducted in ICUs in four hospitals applying the definitions for nosocomial infections of the U.S. Centers for Disease Control and Prevention National Nosocomial Infections Surveillance System (CDC-NNIS) and National Healthcare Safety Network (NHSN). RESULTS: From September 2003 to October 2007 1 920 patients hospitalized in ICUs for an aggregate of 9 997 days acquired 249 DAIs, accounting for a rate of 13.0% and 24.9 DAIs per 1 000 ICU-days. The ventilator-associated pneumonia (VAP) rate was 31.3 per 1 000 ventilator-days; the central venous catheter-associated bloodstream infections (CVC-BSI) rate was 7.7 cases per 1 000 catheter-days; and the rate for catheter-associated urinary tract infections (CAUTI) was 5.1 cases per 1 000 catheter-days. Extra mortality for VAP was 24.5% (RR 2.07, P < 0.001); for CVC-BSI the rate was 15.0% (RR 2.75, P = 0.028). Methicillin-resistant strains accounted for 73.5% of all Staphylococcus aureus DAIs; 40.5% of the Enterobacteriaceae were resistant to ceftriaxone, 40.8% were resistant to ceftazidime, and 32.0% were resistant to piperacillin-tazobactam. Sixty-five percent of Pseudomonas aeruginosa isolates were resistant to ciprofloxacin, 62.0% were resistant to ceftazidime, 29.4% were resistant to piperacillin-tazobactam, and 36.1% were resistant to imipenem. CONCLUSIONS: The high rates of DAIs in the Peruvian hospitals in this study indicate the need for active infection control. Programs consisting of surveillance of DAIs and implementation of guidelines for infection prevention can ensure improved patient safety in the ICUs and throughout hospitals.
OBJECTIVES: To measure device-associated infection (DAI) rates, microbiological profiles, bacterial resistance, and attributable mortality in intensive care units (ICUs) in hospitals in Peru that are members of the International Nosocomial Infection Control Consortium (INICC). METHODS: Prospective cohort surveillance of DAIs was conducted in ICUs in four hospitals applying the definitions for nosocomial infections of the U.S. Centers for Disease Control and Prevention National Nosocomial Infections Surveillance System (CDC-NNIS) and National Healthcare Safety Network (NHSN). RESULTS: From September 2003 to October 2007 1 920 patients hospitalized in ICUs for an aggregate of 9 997 days acquired 249 DAIs, accounting for a rate of 13.0% and 24.9 DAIs per 1 000 ICU-days. The ventilator-associated pneumonia (VAP) rate was 31.3 per 1 000 ventilator-days; the central venous catheter-associated bloodstream infections (CVC-BSI) rate was 7.7 cases per 1 000 catheter-days; and the rate for catheter-associated urinary tract infections (CAUTI) was 5.1 cases per 1 000 catheter-days. Extra mortality for VAP was 24.5% (RR 2.07, P < 0.001); for CVC-BSI the rate was 15.0% (RR 2.75, P = 0.028). Methicillin-resistant strains accounted for 73.5% of all Staphylococcus aureusDAIs; 40.5% of the Enterobacteriaceae were resistant to ceftriaxone, 40.8% were resistant to ceftazidime, and 32.0% were resistant to piperacillin-tazobactam. Sixty-five percent of Pseudomonas aeruginosa isolates were resistant to ciprofloxacin, 62.0% were resistant to ceftazidime, 29.4% were resistant to piperacillin-tazobactam, and 36.1% were resistant to imipenem. CONCLUSIONS: The high rates of DAIs in the Peruvian hospitals in this study indicate the need for active infection control. Programs consisting of surveillance of DAIs and implementation of guidelines for infection prevention can ensure improved patient safety in the ICUs and throughout hospitals.
Authors: V D Rosenthal; P Lynch; W R Jarvis; I A Khader; R Richtmann; N B Jaballah; C Aygun; W Villamil-Gómez; L Dueñas; T Atencio-Espinoza; J A Navoa-Ng; M Pawar; M Sobreyra-Oropeza; A Barkat; N Mejía; C Yuet-Meng; A Apisarnthanarak Journal: Infection Date: 2011-07-06 Impact factor: 3.553
Authors: H Leblebicioglu; A N Yalcin; V D Rosenthal; I Koksal; F Sirmatel; S Unal; H Turgut; D Ozdemir; G Ersoz; C Uzun; S Ulusoy; S Esen; F Ulger; A Dilek; H Yilmaz; O Turhan; N Gunay; E Gumus; O Dursun; G Yýlmaz; S Kaya; H Ulusoy; M Cengiz; L Yilmaz; G Yildirim; A Topeli; S Sacar; H Sungurtekin; D Uğurcan; M F Geyik; A Şahin; S Erdogan; A Kaya; N Kuyucu; B Arda; F Bacakoglu Journal: Infection Date: 2013-01-26 Impact factor: 3.553
Authors: Victor Daniel Rosenthal; Ruijie Yin; Sandra Liliana Valderrama-Beltran; Sandra Milena Gualtero; Claudia Yaneth Linares; Guadalupe Aguirre-Avalos; Julio Cesar Mijangos-Méndez; Miguel Ángel Ibarra-Estrada; Luisa Fernanda Jimenez-Alvarez; Lidia Patricia Reyes; Carlos Arturo Alvarez-Moreno; Maria Adelia Zuniga-Chavarria; Ana Marcela Quesada-Mora; Katherine Gomez; Johana Alarcon; Jose Millan Oñate; Daisy Aguilar-De-Moros; Elizabeth Castaño-Guerra; Judith Córdoba; Alejandro Sassoe-Gonzalez; Claudia Marisol Millán-Castillo; Lissette Leyva Xotlanihua; Lina Alejandra Aguilar-Moreno; Juan Sebastian Bravo Ojeda; Ivan Felipe Gutierrez Tobar; Mary Cruz Aleman-Bocanegra; Clara Veronica Echazarreta-Martínez; Belinda Mireya Flores-Sánchez; Yuliana Andrea Cano-Medina; Edwin Giovannny Chapeta-Parada; Rafael Antonio Gonzalez-Niño; Maria Isabel Villegas-Mota; Mildred Montoya-Malváez; Miguel Ángel Cortés-Vázquez; Eduardo Alexandrino Medeiros; Dayana Fram; Daniela Vieira-Escudero; Zhilin Jin Journal: J Epidemiol Glob Health Date: 2022-10-05
Authors: Manuel S Rangel-Frausto; Francisco Higuera-Ramirez; Jose Martinez-Soto; Victor D Rosenthal Journal: Ann Clin Microbiol Antimicrob Date: 2010-02-02 Impact factor: 3.944
Authors: Marília M Resende; Sílvio G Monteiro; Bianca Callegari; Patrícia M S Figueiredo; Cinara R A V Monteiro; Valério Monteiro-Neto Journal: BMC Infect Dis Date: 2013-03-05 Impact factor: 3.090